Request a quote

Your bridge from ATMPs concept to commercialization

Turn your advanced therapy medicinal products (ATMPs) into clinical reality with targeted technology platforms and expert CRDMO services that support you every step of the way.

Custom Cell and Gene Therapy Services

Streamline your ATMP technical R&D and IND timelines with expert-led development, manufacturing, and QC services. 

From early research to commercial manufacturing, we accelerate your projects with innovative technology development across CGT, mRNA-LNPs, and other ATMP modalities.

Cell and Gene Therapy CDMO Services

Utilize our robust CGT CDMO platforms, optimized for high quality and productivity. We specialize in plasmids, mRNA-LNP, sgRNA, viral vectors, and cell therapy products (CAR-T, CAR-NK, iPSC, MSC).

View CDMO services

Analytical Development & Testing Services

Ensure product integrity and regulatory compliance with our Analytical Development & Testing Services, harnessing state-of-the-art technologies and quality infrastructures.

View Analytical services

Cell and Gene Therapy CRO Services

Support your discovery and preclinical studies with our production services for plasmids, mRNA-LNP, sgRNA, and viruses, including lentivirus, AAV, and adenovirus.

View CRO services
6

Centers of Excellence for manufacturing and testing

>150

GMP batches successfully delivered

20+

INDs filed and accepted with FDA, EMA, and CDE

6

Centers of Excellence for manufacturing and testing

>150

GMP batches successfully delivered

20+

INDs filed and accepted with FDA, EMA, and CDE

Cell and Gene Therapy Products

Accelerate your discovery studies, GMP manufacturing, and analytical assay development with our ready-to-use cell and gene products, available in R&D and GMP grades.

With a perfect audit record from over 100 clients, our products are optimally designed for efficacy, safety, and reliability.

Fast and traceable production

Robust technical expertise and support

High-quality and tested products

Plasmid Products

Access ready-for-use GMP-grade AAV and LVV helper plasmids.

Activated Drug Master Files (DMF)

Save time on your viral vector GMP manufacturing

AAV Products

Discover our AAV empty capsids, available in various serotypes.

Chromatography purified

Extensively characterized AAV empty capsids

Lentivirus Products

Utilize our GFP, GFP-Luciferase, and CD19-CAR lentiviral vectors for potency, efficacy, and CAR-T studies.

Chromatography purified & high transduction efficiency

Potent and tested

iPSC Products

Discover our iPSC generation products, reprogramming cocktail, and CRISPR gene editing mRNA-LNP.

Highly efficient mRNA-LNP reprogramming cocktail

Robust in iPSC generation

Ubrinuclease

Integrate our Ubrinuclease into your cell and gene therapy and biologics manufacturing processes.

GMP-grade, fully QC released

With DNA & RNA nuclease activities

uBriGene Maryland,USA headquarters building

About Us

Headquartered in Maryland, USA, and operating across North America and Asia, uBriGene is a global leader in ATMPs, cell and gene therapy CDMO services, and testing.

With cutting-edge GMP facilities and integrated technology platforms, we build the bridge that transforms your ATMP concepts into tomorrow’s therapies. Our expertise spans preclinical studies, IND enabling,  to commercialization, ensuring seamless development at every stage.

Featured Resources

CAR-T Brochure

Discover the manufacturing processes behind CAR-T cell therapies.

mRNA/LNP Brochure

Learn how we enhance LVV productivity through cell suspension techniques.

LVV Brochure

Explore our mRNA/LNP platform for enhanced therapy delivery.

Recent News

Technology

New Service Launch - Cell Therapy Potency Analytical Development and GMP Testing

March 12, 2024

uBriGene Biosciences announces its new Cell Therapy Potency Analytical Development and GMP Testing service, launching at the Hanson Wade Cell Therapy Potency Assay Summit in Boston, March 19-21, 2024.

Read Press Release
Corporate

uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO)

March 12, 2024

uBriGene (Boston) Biosciences has completed its asset purchase from Mustang Bio, acquiring a state-of-the-art manufacturing facility in Worcester, Massachusetts, enhancing its production capabilities.

Read Press Release

Upcoming Events

uBriGene to Showcase Innovations at ASH 2024

December 7, 2024 | San Diego, CA, USA

Event website

Upcoming Events

Cell Therapy Potency Assay Summit 2024

March 12, 2024 | Boston, MA

Event Website

Cell Therapy Potency Assay Summit 2024

March 12, 2024 | Boston, MA

Event Website

Cell Therapy Potency Assay Summit 2024

March 12, 2024 | Boston, MA

Event Website